Interviews

Christopher Simon

2024-04-15

Haemonetics operates across two primary segments: collections (plasma and blood centers) and hospital solutions. The collections segment focuses on sourcing plasma and blood for biopharmaceutical products and transfusion medicine, respectively.

Markus Warmuth

Monte Rosa Therapeutics

CEO, Monte Rosa Therapeutics

2024-04-15

For Monte Rosa, the focus remains on advancing quality science and drug candidates. The company has maintained a positive performance, attributed to its leadership in molecular glue degraders and a unique portfolio that includes promising partnerships, underscoring confidence in its platform and the potential of its lead candidates.

Seth Lederman

Co founder & CEO

Tonix Pharmaceuticals

2024-04-12

We are excited for the possibility to be one of the new non-opiate drugs that represent the post-opiate-crisis wave of innovation.

Christina Mainelli

CEO

Quartet Health

2024-04-12

Additionally, Quartet directly delivers care through its medical group, and is a trusted partner of health plans, health systems, and community mental health centers that serve patients in 39 states across the country, all in service of its mission to improve individual and community health by ensuring the delivery of optimal care for those in need.

Terrence Moorehead

CEO

Nature’s Sunshine Product

2024-04-12

The emphasis on clinically significant ingredient levels and the use of potent, bioavailable components contribute to the products' effectiveness, fostering a loyal customer base that experiences real results from Nature Sunshine's offerings.

Kyoko (Kay) Deguchi

CEO

PHC Group

2024-04-12

The ability to translate our vast technological and human resources into tangible healthcare solutions is crucial.

Glenn Hunzinger

US Pharma and Life Sciences Leader

PwC

2024-04-12

In the future, the life sciences industry is likely to be significantly influenced by the increasing consumerism in healthcare.

Sebastian Guth

Chief Operating Officer for Bayer Pharmaceuticals and President at Bayer US

Bayer

2024-04-12

For Bayer, technology is not just about innovation for its own sake but about how it can be leveraged to make a real impact on patient care.

Fabian Gerlinghaus

CEO & Co-Founder

Cellares

2024-04-11

About 20% of patients are dying on the waitlist even though they are eligible for approved cell therapies because the industry is unable to meet patient demand. This is largely due to the lack of automated, high-throughput cell therapy manufacturing technologies.

Dr. Abdulkader Rahmo

President and CSO

SMSbiotech

2024-04-11

SMS cells possess distinct characteristics in terms of stability, size, shape, and specific binding abilities to crucial cells in the body, such as progenitor stem cells and mesenchymal stem cells.

Pagina 61 din 154